Literature DB >> 2982011

Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.

A Tempel, E L Gardner, R S Zukin.   

Abstract

The neurochemical and functional correlates of opioid receptor up-regulation after chronic antagonist administration in vivo and of down-regulation after withdrawal of antagonist were examined. Total brain opioid receptors increased 1.9-fold by day 8 of naltrexone administration, after which no further increase was observed; the newly synthesized or unmasked receptors exhibited an enhanced sensitivity to guanyl nucleotide modulation. Withdrawal from chronic naltrexone treatment resulted in a return to nearly control levels of receptor density and guanyl nucleotide sensitivity in a period of 6 days. These results suggest that up-regulation is accompanied by an increased coupling of the receptors to the inhibitory guanyl nucleotide binding protein (Ni) and that down-regulation involves the dissociation of the receptor/Ni complex. In experiments designed to target opiate receptor subtypes, long-term treatment with naltrexone was found to produce a coordinated up-regulation of brain mu and delta receptors, but did not cause a significant change in the density or affinity of kappa or sigma receptors. These findings indicate that the kappa and sigma opiate receptor classes may be subject to independent control mechanisms. Chronic naltrexone treatment also resulted in an enhanced morphine-induced analgesia. This result indicates that a functional supersensitivity occurs as a result of the selective up-regulation of mu and delta receptors. After withdrawal from naltrexone, supersensitivity to morphine-induced analgesia decreased monotonically and, in parallel to opioid receptor density, to prenaltrexone treatment levels within 6 days. Together, these results suggest a functional significance for antagonist-induced mu and delta opiate receptor up-regulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982011

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice.

Authors:  Alexis Bailey; Rachel M Hawkins; Susanna M O Hourani; Ian Kitchen
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

2.  Involvement of mu-opioid receptors in the antitussive effects of pentazocine.

Authors:  J Kamei; K Katsuma; Y Kasuya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

3.  Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone.

Authors:  A M Young; S R Mattox; M D Doty
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Conditioning of morphine-induced taste aversion and analgesia.

Authors:  J S Miller; K S Kelly; J L Neisewander; D F McCoy; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers.

Authors:  James W Cornish; David Henson; Sanford Levine; Joseph Volpicelli; Charles E Inturrisi; Byron C Yoburn; Charles P O'Brien
Journal:  Am J Addict       Date:  1993

6.  Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.

Authors:  An-Li Wang; Steven B Lowen; Igor Elman; Zhenhao Shi; Victoria P Fairchild; Alexander Bouril; Ruben C Gur; Daniel D Langleben
Journal:  J Subst Abuse Treat       Date:  2017-10-18

7.  "Paradoxical" analgesia induced by naloxone and naltrexone.

Authors:  J D Greeley; A D Lê; C X Poulos; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Pharmacological specificity of enhanced sensitivity to naltrexone in rats.

Authors:  C W Schindler; S R Goldberg; J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone.

Authors:  Ingrid A Binswanger; Jason M Glanz
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

10.  Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing.

Authors:  C X Poulos; D M Knoke; A D Le; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.